leisure time -WSS

leisure time

author：explore 2025-10-02 01:05:01 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

WSS

New documents shed light on MD Anderson Cancer Institute feud

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

He's a Nobel laureate. Critics say he was misleading on Covid

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

focus

leisure time

Gilead needs Arcellx more than ever

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Novavax promises a turnaround & Lilly roils the obesity market

He's a Nobel laureate. Critics say he was misleading on Covid

Moonlake's readout produced a cash windfall. Risks remain

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Apple is now the first public company to be valued at $3 trillion

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Activists slam private health insurers over coverage restrictions

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

focus

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

PBM reform efforts get punted in Congress

NYC plans to house migrants on an island in the East River

Ed Silverman on new gene therapies, biosimilars, coffee, and more

At least 12 people were injured in a blast at a port in northwest Turkey

entertainment

explore

explore

leisure time